NantKwest Continues the Strengthening of Its Leadership Team and Appoints a Seasoned Bioprocessing Manufacturing Executive

Oct 6, 2015

Stephen Farrand, Ph.D., former Merck executive appointed Senior Vice President Global Manufacturing

CULVER CITY, Calif.–(BUSINESS WIRE)–Oct. 6, 2015– NantKwest, Inc. (Nasdaq: NK), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using natural killer cells to treat cancer, infectious diseases and inflammatory diseases, today announced the appointment of Stephen Farrand, Ph. D., as senior vice president of global manufacturing.

“Dr. Farrand is an experienced executive, with an impressive track record of achievement in chemistry, manufacturing and control (CMC) development,” said Patrick Soon-Shiong, M.D., chairman and chief executive officer of NantKwest. “He brings expertise in all aspects of biologics development and manufacturing, as well as a full understanding of cGMP compliance requirements and the regulatory environment. With our recent acquisition of two production sites in Southern California, including a 45,000 square foot facility in Torrey Pines, Dr. Farrand fills a key function as we expand in-house production capacity for our aNK, haNK and taNK products.”

Prior to joining NantKwest, Dr. Farrand was vice president bioprocess development for Merck Research Laboratories, where his leadership was instrumental to the successful development and commercialization of Merck’s PD-1 checkpoint inhibitor, Keytruda. Previously, he held a number of positions of increasing responsibility with Schering Plough, most recently as vice president global biologics & sterile product development. Before that, Dr. Farrand served in senior level development & manufacturing positions with Delta Biotechnology, Sigma Chemical and G. D. Searle. Dr. Farrand has a PhD in Microbial Physiology from the University of Leicester, UK, and a BSc in Microbiology from the University of Bath, UK.

About NantKwest Inc.

NantKwest (Nasdaq:NK) is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases. NK cells are the body’s first line of defense due to the innate ability of NK cells to rapidly identify and destroy cells under stress, such as cancer or virally-infected cells.

NantKwest’s unique NK cell-based platform, with the capacity to grow active killer cells as a biological cancer therapy, has been designed to induce cell death against cancer or infected cells by three different modes of action: (1) Direct killing using activated NK cells (aNK) that release toxic granules directly into the cell through cell to cell contact, (2) Antibody-mediated killing using haNKs, which are NK cells engineered to incorporate a high affinity receptor that binds to an administered antibody, enhancing the cancer cell killing effect of that antibody, and (3) Targeted activated killing using taNKs, which are NK cells engineered to incorporate chimeric antigen receptors (CARs) to target tumor-specific antigens found on the surface of cancer cells.

Our aNK, haNK and taNK platform addresses certain limitations of T cell therapies including the reduction of risk of serious “cytokine storms” reported after T cell therapy. As an “off-the-shelf” therapy, NantKwest’s NK cells do not rely on a patient’s own often compromised immune system. In Phase 1 clinical trials in patients with late stage cancer, NantKwest’s NK cells have been successfully administered as an outpatient infusion therapy without any reported severe side effects, even at doses of 10 billion cells.

By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs that include a Phase 2 trial for a rare form of melanoma and the planned initiation of a clinical trial of NK cells targeted to breast cancer, we believe NantKwest is uniquely positioned to be the premier immunotherapy company and transform medicine by delivering living drugs in a bag and bringing novel NK cell-based therapies to routine clinical care.

View source version on

Source: NantKwest

Jen Hodson, 562-397-3639

Contact us at


How Can ImmunityBio Help You?

Solutions for Patients

Many cancer therapies, including radiation therapy, chemotherapy, CAR-T therapy, and B-cell immunotherapy, severely weaken the immune system—the human body’s most important natural disease-fighting weapon. But ImmunityBio creates targeted, personalized immunotherapies that are designed to strengthen the immune system and enable it to outsmart your disease.

Opportunities for Trial Investigators

The broad therapeutic potential and demonstrated safety of ImmunityBio’s immune-enhancing IL-15 superagonist Anktiva (N-803), engineered NK-92® cell-based therapies, and our next-generation adenovirus-vectored anti-cancer vaccines make them appealing therapeutics for testing by trial investigators who want to make a contribution to clinical cancer research. Interested clinicians and other are encouraged to contact ImmunityBio to find out how they may support discovery of future cancer treatments.

Tools for Research Scientists

Our NK-92® easy-to-maintain and highly cytotoxic natural killer cell line provides a versatile bioanalytical testing tool that can help researchers develop functional killing assays that are more consistent and reliable than donor blood and reporter gene assays.

ImmunityBio is continuously pursuing new immunotherapies designed to attack disease by enhancing the patient’s immune system, not weakening it.